5-Amino-1MQ

How does 5-Amino-1MQ work?

5-Amino-1MQ is a small-molecule, membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT) — a quinolinium compound, not a peptide. NNMT methylates nicotinamide using S-adenosylmethionine (SAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). By inhibiting NNMT (IC50 ~1 µM), 5-Amino-1MQ relieves that SAM 'methyl sink' and preserves nicotinamide for NAD+ salvage. The downstream metabolic effects below are all from preclinical (rodent and cell) models.

1. NNMT Inhibition. 5-Amino-1MQ is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), with an IC50 of about 1 µM. It is a quinolinium compound and has no amino-acid sequence.
2. Relieving the SAM Methyl Sink. NNMT methylates nicotinamide using S-adenosylmethionine (SAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Inhibiting NNMT relieves this 'methyl sink' on SAM.
3. Preserving Nicotinamide for NAD+ Salvage [1]. By reducing nicotinamide methylation, NNMT inhibition preserves nicotinamide for the NAD+ salvage pathway — associated in preclinical models with increased NAD+.
4. Metabolic Effects in Rodent Models [1]. NNMT inhibition is associated with higher energy expenditure, reduced lipogenesis and adiposity, and preserved lean mass. In diet-induced-obese (DIO) mice, weight and fat-mass reductions occurred without reduced food intake.

What is 5-Amino-1MQ researched for?

5-Amino-1MQ's research base is entirely preclinical, centered on metabolic disease in rodents. The most directly relevant study dosed it once-daily for 28 days in diet-induced-obese mice; supporting work spans the discovery/structure-activity of the inhibitor series, reversal of high-fat-diet obesity by NNMT inhibitors, and a foundational genetic proof-of-concept for NNMT as a metabolic target. There are no human clinical trials.

1. Diet-Induced Obesity in Mice [1]. Once-daily 5-Amino-1MQ for 28 days in diet-induced-obese mice improved body composition and glucose/insulin parameters, with liver-pathology and pharmacokinetic assessments; weight and fat-mass reductions occurred without reduced food intake (Babula et al. 2024). Preclinical.
2. Discovery & Structure-Activity Relationship. The small-molecule NNMT inhibitor series was characterized in a structure-activity-relationship study (Neelakantan et al., J Med Chem 2017). Cited by name.
3. High-Fat-Diet Obesity Reversal. Selective, membrane-permeable small-molecule NNMT inhibitors reversed high-fat-diet-induced obesity in mice (Neelakantan et al., Biochem Pharmacol 2018). Cited by name.
4. Genetic Proof-of-Concept. NNMT knockdown using an antisense oligonucleotide (not a small molecule) protected against diet-induced obesity, establishing NNMT as a metabolic target (Kraus et al., Nature 2014). Cited by name.

How is 5-Amino-1MQ dosed?

There is no validated or FDA-approved dose for 5-Amino-1MQ. It is handled as a research chemical, and the only dosing in the literature comes from preclinical rodent studies.

Preclinical studies administered 5-Amino-1MQ on rodent dosing schedules (for example, once-daily dosing over 28 days in diet-induced-obese mice), but rodent regimens do not translate into a human dose, and Prof. Peptide does not extrapolate one. There is no established human protocol, no validated mg or mg/kg schedule, and — because the compound is supplied as a solid research chemical (commonly the iodide salt) rather than a reconstituted injectable peptide — no reconstitution table is provided. The research material is unapproved and for laboratory use only.

What are the side effects of 5-Amino-1MQ?

The human safety of 5-Amino-1MQ is not characterized. The available evidence is entirely preclinical (rodent and cell models), so there is no controlled human adverse-event data to summarize. This is an unapproved, Research Use Only research chemical and is not intended for human consumption; nothing here should be read as human-use guidance. Long-term safety is unknown.

How should 5-Amino-1MQ be stored?

1. Solid (powder) form, commonly supplied as the iodide salt: store cold and desiccated, protected from light.
2. Keep tightly sealed in the original container; protect from moisture and light.
3. For long-term storage, store frozen (-20°C); short-term storage at 2–8°C is acceptable.
4. If dissolved for laboratory use, keep the solution cold and protected from light, and handle promptly.
5. Discard if the material is discolored or shows signs of degradation.

What are the limitations of 5-Amino-1MQ research?

This is the most important section to read carefully. Everything known about 5-Amino-1MQ comes from preclinical models, and it is a research chemical rather than an approved medicine.

Where to source 5-Amino-1MQ

5-Amino-1MQ is an unapproved research chemical sold by specialty research vendors for laboratory use only. Quality varies across vendors; verify a Certificate of Analysis before purchase.

5-Amino-1MQ FAQ

References

1. Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. PMID 39161060. https://pubmed.ncbi.nlm.nih.gov/39161060/
2. Neelakantan H, et al. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. J Med Chem. 2017;60(12):5015-5028. (Cited by name; no link added.)
3. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high-fat-diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. (Cited by name; no link added.)
4. Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. (Foundational genetic proof-of-concept, antisense-oligonucleotide knockdown rather than small-molecule; cited by name, no link added.)
5. Chemical identifiers: PubChem CID 950107; CAS 42464-96-0 (iodide salt); cation formula C10H11N2(+); cation molecular weight ~159.21 g/mol. (Cited by name/ID, no URL added.)

Published Studies